Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Extends Offer for Dionex

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market Tuesday that it has extended until midnight, New York City time, on April 7, its tender offer to acquire all of the outstanding shares of Dionex.

Thermo Fisher inked the deal in December to acquire Dionex for $118.50 per share in cash for a total transaction value of $2.1 billion. The tender offer represented a 21 percent premium to Dionex's closing share price of $98.17 on Dec. 10, the last trading day prior to the announcement.

As of 5:00 pm, New York City time, on Feb. 15, approximately 9.1 million shares of Dionex's common stock, representing around 52 percent of all outstanding shares, had been tendered and not withdrawn from the offer.

The deal already has cleared US antitrust review, and Thermo Fisher expects to close the deal early in the second quarter, it said yesterday.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.